Researchers at the Mayo Clinic are using autologous (the patients’ own) stem cells to treat a rare congenital heart defect. For infants born with hypoplastic left heart syndrome, the first few months of life are a complicated battle that involves several reconstructive surgeries that repair the underdeveloped left portion of the heart and help the right side maintain the increased load. The infants are participating in a Phase I clinical trial after being diagnosed with the syndrome before birth. At birth, the researchers obtained the patients’ cord blood stem cells and cryopreserved them until the second reconstructive operation of the heart, which typically follows a few months after birth. The researchers injected the patients’ stem cells into the affected site of the heart to support and strengthen the weakened cardiac muscle in the area.
This revolutionary study illustrates how personalized medicine is evolving to treat patients with rare disorders utilizing their own stem cells, eliminating both the need to find a donor and the risk of cell rejection. The study also demonstrates the wisdom of cryopreserving stem cells [when they are young, active and plentiful] for future use as the most optimal way to assure access to emerging regenerative therapies, particularly for patients with rare disorders.
This innovative research demonstrates the integral role stem cells are playing in cutting edge medical care options. By banking their own valuable stem cells, families can ensure that they will have access to these emerging therapies in the near future. To learn more about banking stem cells, please visit StemSave or call 877-783- 6728 (877-StemSave) today.
The Future of Regenerative Medicine is Now™
To view the full article, click here.